港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

銀諾醫藥-B

3.635

-0.160-4.22%

成交量：539.13萬

成交額：1,966.84萬

市值：16.61億

市盈率：-3.94

高：3.800

開：3.800

低：3.605

收：3.795

52周最高：48.360

52周最低：3.605

股本：4.57億

香港流通股本：4.20億

量比：0.71

換手率：1.28%

股息：- -

股息率：- -

每股收益(LYR):-0.922

淨資產收益率：-41.16%

總資產收益率：-20.15%

市淨率：1.51

市盈率(LYR):-3.94

市銷率: 9.29

資料載入中...

總覽公司新聞公告

異動解讀 | 銀諾醫藥-B盤中大跌5.79%，年度虧損大幅擴大引發市場擔憂

從商業化跨越到全球領跑，銀諾醫藥（2591.HK）解碼超長效GLP-1的稀缺價值

銀諾醫藥-B(02591)發布2025年度業績，淨虧損3.41億元，按年擴大95.4%

銀諾醫藥-B：2025年度收入約1.31509億元，多適應症佈局加速推進

銀諾醫藥-B(02591)：麥寶文獲委任為聯席公司秘書

港股異動 | 銀諾醫藥-B(02591)盤中跌超5% 預期年度產生虧損約3.414億元年內研發開支增加

銀諾醫藥-B(02591)發盈警預期2025年產生虧損約3.414億元

智通财经网

銀諾醫藥-B預計全年虧損擴大研發投入激增1.03億元

銀諾醫藥-B（02591）：預計2025年度虧損擴大至約3.41億元

銀諾醫藥－Ｂ(02591)股價上升5.126%，現價港幣$23.38

阿斯达克财经

銀諾醫藥-B(02591)擬實施H股全流通計劃

IPO「黑函」頻現港交所「密交」擴容箭在弦上

21世纪经济报道

銀諾醫藥-B(02591.HK)3月23日舉行董事會會議考慮及批准全年業績

銀諾醫藥新獸藥推進6000L產能工藝變更申報

兽药信息资讯

銀諾醫藥-B03月05日獲主力加倉53.6萬元

浦東創新藥上市首年即進駐上海50+醫療機構，創新落地「不減速」！浦東全鏈條支撐顯成效

銀諾醫藥-B（02591）2月股份變動月報：股本保持穩定

銀諾醫藥-B盤中異動股價大跌5.43%報23.000港元

世界肥胖日｜告別"周拋"針！銀諾醫藥積極探索"每月一針"減重新方案

銀諾醫藥-B盤中異動早盤股價大跌5.40%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/02591/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02591","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"銀諾醫藥-B","latestPrice":3.635,"timestamp":1788163728003,"preClose":3.795,"halted":0,"volume":5391344,"delay":0,"changeRate":-0.04216073781291176,"floatShares":420285370,"shares":457000000,"eps":-0.9216336400834025,"marketStatus":"未開盤","change":-0.16,"latestTime":"08-31 16:08:48","open":3.8,"high":3.8,"low":3.605,"amount":19668366,"amplitude":0.051383,"askPrice":3.64,"askSize":2600,"bidPrice":3.635,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-0.8594583681235989,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":3.795,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.708645,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","floatShares":420285370,"roa":"-20.15%","roe":"-41.16%","lyrEps":-0.921634,"volumeRatio":0.708645,"shares":457000000,"dividePrice":0,"high":3.8,"amplitude":0.051383,"preClose":3.795,"low":3.605,"week52Low":3.605,"pbRate":"1.51","psRate":"9.29","week52High":48.36,"institutionHeld":0,"latestPrice":3.635,"committee":0.395349,"eps":-0.9216336400834025,"divideRate":0,"volume":5391344,"delay":0,"ttmEps":-0.8594583681235989,"open":3.8,"prevYearClose":30.64,"prevWeekClose":3.795,"prevMonthClose":7.26,"prevQuarterClose":7.09,"fiveDayClose":4.065,"twentyDayClose":7.09,"sixtyDayClose":9.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02591\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"02591","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-29","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02591\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02591\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1775923200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02591\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02591","date":"2026-08-28","current":-4.230943,"percent":1,"low":-137.156472,"twenty":-68.330506,"median":-49.617462,"eighty":-11.852702,"high":-4.445704,"avg":-44.9056,"sd":30.195085,"marketCap":1733629429},"quantilePoints":[{"date":"2025-08-15","current":-137.156472,"twenty":-137.156472,"median":-137.156472,"eighty":-137.156472,"marketCap":26152907730},{"date":"2025-08-22","current":-127.373977,"twenty":-129.344203,"median":-127.373977,"eighty":-126.417438,"marketCap":24211425497},{"date":"2025-08-29","current":-106.390102,"twenty":-127.373977,"median":-126.095992,"eighty":-114.007182,"marketCap":20319324643},{"date":"2025-09-05","current":-78.151342,"twenty":-127.373977,"median":-117.586994,"eighty":-99.491273,"marketCap":18939730209},{"date":"2025-09-12","current":-83.843855,"twenty":-126.417438,"median":-105.433356,"eighty":-83.374192,"marketCap":20355870191},{"date":"2025-09-19","current":-79.271387,"twenty":-126.095992,"median":-93.890147,"eighty":-81.90749,"marketCap":19232094592},{"date":"2025-09-26","current":-78.986763,"twenty":-125.916102,"median":-85.498552,"eighty":-79.429082,"marketCap":19113321562},{"date":"2025-10-03","current":-76.5387,"twenty":-122.116665,"median":-83.843855,"eighty":-78.76383,"marketCap":18565138343},{"date":"2025-10-10","current":-69.068341,"twenty":-116.871032,"median":-83.374192,"eighty":-77.810518,"marketCap":16728724560},{"date":"2025-10-17","current":-67.838616,"twenty":-109.436934,"median":-79.738352,"eighty":-74.826182,"marketCap":16418087403},{"date":"2025-10-24","current":-59.813644,"twenty":-105.816054,"median":-79.429082,"eighty":-68.576451,"marketCap":14481173363},{"date":"2025-10-31","current":-57.61442,"twenty":-103.460611,"median":-78.986763,"eighty":-66.346017,"marketCap":13969535692},{"date":"2025-11-07","current":-56.556997,"twenty":-100.097405,"median":-78.243448,"eighty":-63.14919,"marketCap":13704580470},{"date":"2025-11-14","current":-61.96171,"twenty":-95.010372,"median":-77.299283,"eighty":-61.326336,"marketCap":15056765743},{"date":"2025-11-21","current":-54.467459,"twenty":-87.179427,"median":-75.823033,"eighty":-60.1184,"marketCap":13229488347},{"date":"2025-11-28","current":-82.342484,"twenty":-85.508442,"median":-76.5387,"eighty":-60.703449,"marketCap":20072642195},{"date":"2025-12-05","current":-82.313405,"twenty":-85.248884,"median":-75.823033,"eighty":-61.326336,"marketCap":20100051356},{"date":"2025-12-12","current":-63.824496,"twenty":-84.462171,"median":-74.404407,"eighty":-61.326336,"marketCap":15614085348},{"date":"2025-12-19","current":-62.072323,"twenty":-83.725798,"median":-74.049705,"eighty":-60.286674,"marketCap":15221220708},{"date":"2025-12-24","current":-59.762449,"twenty":-83.548712,"median":-73.276127,"eighty":-59.816947,"marketCap":14700446650},{"date":"2026-01-02","current":-56.27243,"twenty":-83.409096,"median":-71.366231,"eighty":-59.572219,"marketCap":13896444596},{"date":"2026-01-09","current":-57.1291,"twenty":-82.548826,"median":-69.803372,"eighty":-58.239982,"marketCap":14143127045},{"date":"2026-01-16","current":-56.980838,"twenty":-82.319221,"median":-67.499105,"eighty":-57.682607,"marketCap":14152263432},{"date":"2026-01-23","current":-58.213825,"twenty":-82.096799,"median":-66.291021,"eighty":-57.601428,"marketCap":14444627815},{"date":"2026-01-30","current":-54.613459,"twenty":-81.934522,"median":-64.906051,"eighty":-57.510573,"marketCap":13613216600},{"date":"2026-02-06","current":-49.064319,"twenty":-80.235292,"median":-63.834,"eighty":-57.242442,"marketCap":12261031327},{"date":"2026-02-13","current":-50.165477,"twenty":-79.691019,"median":-62.941647,"eighty":-57.039695,"marketCap":12608214032},{"date":"2026-02-20","current":-50.419859,"twenty":-79.623791,"median":-62.643943,"eighty":-56.891323,"marketCap":12653895967},{"date":"2026-02-27","current":-50.052949,"twenty":-79.470699,"median":-62.017016,"eighty":-56.651056,"marketCap":12699577902},{"date":"2026-03-06","current":-43.88908,"twenty":-79.397543,"median":-60.902753,"eighty":-56.29247,"marketCap":11045891858},{"date":"2026-03-13","current":-39.965904,"twenty":-79.214462,"median":-60.292057,"eighty":-54.71959,"marketCap":10104843999},{"date":"2026-03-20","current":-39.174717,"twenty":-78.964109,"median":-59.813644,"eighty":-50.865048,"marketCap":9867297938},{"date":"2026-03-27","current":-24.701097,"twenty":-78.775514,"median":-59.491697,"eighty":-50.290678,"marketCap":9547524394},{"date":"2026-04-02","current":-24.535908,"twenty":-78.383597,"median":-58.823921,"eighty":-50.052949,"marketCap":9529251620},{"date":"2026-04-10","current":-24.978414,"twenty":-78.348547,"median":-58.584467,"eighty":-49.631191,"marketCap":9775934068},{"date":"2026-04-17","current":-23.474521,"twenty":-78.227102,"median":-58.112982,"eighty":-48.421657,"marketCap":9191205301},{"date":"2026-04-24","current":-19.658213,"twenty":-78.155492,"median":-57.844151,"eighty":-44.116877,"marketCap":7697406030},{"date":"2026-04-30","current":-16.329046,"twenty":-77.825679,"median":-57.660489,"eighty":-41.074266,"marketCap":6395470886},{"date":"2026-05-08","current":-17.822364,"twenty":-77.322024,"median":-57.626503,"eighty":-40.478309,"marketCap":5778764764},{"date":"2026-05-15","current":-17.368107,"twenty":-77.157551,"median":-57.517602,"eighty":-40.012158,"marketCap":5646287153},{"date":"2026-05-22","current":-17.112125,"twenty":-76.782452,"median":-57.446424,"eighty":-25.37304,"marketCap":5550355090},{"date":"2026-05-29","current":-15.607197,"twenty":-76.252433,"median":-57.23775,"eighty":-24.916387,"marketCap":5079831160},{"date":"2026-06-05","current":-14.014909,"twenty":-75.020932,"median":-57.073515,"eighty":-24.414835,"marketCap":4568193490},{"date":"2026-06-12","current":-11.752443,"twenty":-74.621039,"median":-56.924891,"eighty":-23.900197,"marketCap":3828146144},{"date":"2026-06-18","current":-10.549084,"twenty":-74.404407,"median":-56.73827,"eighty":-23.474521,"marketCap":3444417891},{"date":"2026-06-26","current":-9.60263,"twenty":-74.160764,"median":-56.642046,"eighty":-20.865982,"marketCap":3120076153},{"date":"2026-07-03","current":-11.351574,"twenty":-74.088566,"median":-56.533624,"eighty":-19.581214,"marketCap":3691100339},{"date":"2026-07-10","current":-11.238926,"twenty":-74.037218,"median":-56.208644,"eighty":-19.055481,"marketCap":3649986598},{"date":"2026-07-17","current":-10.540302,"twenty":-73.42668,"median":-55.144116,"eighty":-17.753872,"marketCap":3435281504},{"date":"2026-07-24","current":-10.636027,"twenty":-71.947117,"median":-53.621015,"eighty":-17.028947,"marketCap":3467258858},{"date":"2026-07-31","current":-10.1543,"twenty":-71.465685,"median":-51.153424,"eighty":-16.590446,"marketCap":3316508473},{"date":"2026-08-07","current":-10.609247,"twenty":-70.999854,"median":-50.412223,"eighty":-15.817726,"marketCap":3471827052},{"date":"2026-08-14","current":-9.215586,"twenty":-70.625283,"median":-50.222782,"eighty":-14.020929,"marketCap":3019575896},{"date":"2026-08-21","current":-5.675745,"twenty":-69.656366,"median":-50.052949,"eighty":-12.083492,"marketCap":1863822943},{"date":"2026-08-28","current":-4.445704,"twenty":-68.330506,"median":-49.617462,"eighty":-11.852702,"marketCap":1733629429}],"updateTime":1788182604548},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02591\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1154228635","title":"異動解讀 | 銀諾醫藥-B盤中大跌5.79%，年度虧損大幅擴大引發市場擔憂","url":"https://stock-news.laohu8.com/highlight/detail?id=1154228635","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154228635?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:42","pubTimestamp":1774316545,"startTime":"0","endTime":"0","summary":"银诺医药-B(02591)今日盘中股价大跌5.79%，引起了投资者的广泛关注。消息面上，公司于近期发布了截至2025年12月31日止年度的业绩报告。报告显示，公司期内收入约为1.315亿元人民币，但净亏损高达3.41亿元，同比大幅扩大95.4%，每股基本亏损0.79元，且公司宣布不派发股息。这份业绩报告显示公司亏损额显著增加，远超市场预期，这直接打击了投资者信心，导致股价在交易时段承压下行。市场分析认为，亏损的急剧扩大反映了公司当前面临的经营挑战，引发了投资者对其未来盈利能力的担忧。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621392850","title":"從商業化跨越到全球領跑，銀諾醫藥（2591.HK）解碼超長效GLP-1的稀缺價值","url":"https://stock-news.laohu8.com/highlight/detail?id=2621392850","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621392850?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:33","pubTimestamp":1774316026,"startTime":"0","endTime":"0","summary":"银诺医药即将迎来一场由“现金流打底+管线弹性”驱动的系统性价值重估","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4158939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["GLP","BK4590","02591","BK4144","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621575707","title":"銀諾醫藥-B(02591)發布2025年度業績，淨虧損3.41億元，按年擴大95.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621575707","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621575707?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 23:10","pubTimestamp":1774278609,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布截至2025年12月31日止年度业绩，集团产生约1.315亿元(人民币，下同)的收入，主要来自于在中国销售依苏帕格鲁肽α。净亏损3.41亿元，同比扩大95.4%;每股基本亏损0.79元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"银诺医药-B(02591)发布2025年度业绩，净亏损3.41亿元，同比扩大95.4%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110146498","title":"銀諾醫藥-B：2025年度收入約1.31509億元，多適應症佈局加速推進","url":"https://stock-news.laohu8.com/highlight/detail?id=1110146498","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110146498?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 22:59","pubTimestamp":1774277983,"startTime":"0","endTime":"0","summary":"于2025年度，银诺医药-B收入约1.31509亿元，主要来自在中国内地销售核心产品依薛帕格鲁α，销售成本约0.14452亿元，毛利约1.17057亿元，毛利率约89.0%。同期研发开支约2.05779亿元、行政开支约0.77400亿元、销售及分销开支约1.76645亿元，全年亏损约3.41363亿元。管理层指出，较高的研发及推广投入导致亏损保持在较大规模。依薛帕格鲁α已纳入国家医保药品目录，为后续人群适应症的拓展奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703555","title":"銀諾醫藥-B(02591)：麥寶文獲委任為聯席公司秘書","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703555","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703555?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 20:07","pubTimestamp":1774267670,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，施雪玲女士已辞任(i)本公司联席公司秘书、(ii)本公司法律程序文件代理人(根据香港法例第622章公司条例第16部在香港代本公司接收法律程序文件和根据香港联合交易所有限公司证券上市规则第19A.13(2)条在香港代本公司接收法律程序文件或通知之法律程序文件代理人，以及(iii)担任根据上市规则第3.05条的本公司授权代表，基于个人职业发展原因，自2026年3月23日起生效。麦宝文女士已获委任为(i)联席公司秘书、(ii)法律程序代理人及(iii)授权代表，自2026年3月23日起生效。杨东妍女士一直担任并将继续担任另一位联席公司秘书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620201133","title":"港股異動 | 銀諾醫藥-B(02591)盤中跌超5% 預期年度產生虧損約3.414億元 年內研發開支增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2620201133","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620201133?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 11:48","pubTimestamp":1773978490,"startTime":"0","endTime":"0","summary":"消息面上，3月18日，银诺医药-B发布公告，尽管用于治疗2型糖尿病的依苏帕格鲁肽α于中国及澳门商业化上市后，集团于2025年度取得收益约人民币1.315亿元，集团预期本年度将取得亏损约人民币3.414亿元，而截至2024年12月31日止年度则取得亏损约人民币1.747亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02591","VXUS","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620970235","title":"銀諾醫藥-B(02591)發盈警 預期2025年產生虧損約3.414億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620970235","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620970235?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 16:37","pubTimestamp":1773823033,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B 公布，尽管用于治疗2型糖尿病的依苏帕格鲁肽α于中国及澳门商业化上市后，集团于2025年度取得收益约人民币1.315亿元，集团预期本年度将取得亏损约人民币3.414亿元，而截至2024年12月31日止年度则取得亏损约人民币1.747亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"银诺医药-B(02591)发盈警 预期2025年产生亏损约3.414亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197852552","title":"銀諾醫藥-B預計全年虧損擴大 研發投入激增1.03億元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197852552","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197852552?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 16:37","pubTimestamp":1773823032,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司近日发布盈利预警公告，预计2023财年将录得显著亏损。公司指出，亏损主要源于研发费用的大幅增加，期内研发支出同比激增约1.03亿元人民币，同时销售及分销成本也有所上升。此次研发费用的大幅增长，反映了银诺医药在创新药管线上的持续投入。银诺医药-B的股价表现将在一定程度上取决于其核心产品能否取得突破性进展，以及公司现金储备能否支撑其研发计划至关键节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178999501","title":"銀諾醫藥-B（02591）：預計2025年度虧損擴大至約3.41億元","url":"https://stock-news.laohu8.com/highlight/detail?id=1178999501","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178999501?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 16:36","pubTimestamp":1773822994,"startTime":"0","endTime":"0","summary":"银诺医药-B3月18日晚间发布盈利预警称，预计2025年度将录得归属于母公司所有者的亏损约3.41亿元，而上年同期亏损约1.75亿元。期内，公司实现收入约1.32亿元，主要来自核心产品依苏帕格鲁肽α在中国及澳门上市后的商业化销售，上年同期收入为零。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620880092","title":"銀諾醫藥－Ｂ(02591)股價上升5.126%，現價港幣$23.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2620880092","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620880092?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 10:15","pubTimestamp":1773800100,"startTime":"0","endTime":"0","summary":"[上升股]银诺医药－Ｂ(02591) 股价在上午10:15比前收市价上升5.126%，现股价为港币$23.38。至目前为止，今日最高价为$23.38，而最低价为$22.0。总成交量为5.7万股，总成交金额为港币$129.277万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318601/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318601/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620425636","title":"銀諾醫藥-B(02591)擬實施H股全流通計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=2620425636","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620425636?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 18:38","pubTimestamp":1773743905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，于2026年3月17日，本公司已就建议将公司的全部境内未上市股份转换为本公司H股向中国证监会提交备案申请。于取得所有相关批准及 ╱ 或备案(包括中国证监会的备案通知及联交所的批准)及遵守所有适用法律、规则及法规后，该等境内非上市股份将转换为H股，而本公司将申请批准该等H股于联交所主板上市及买卖。根据本公司的组织章程细则，转换及上市毋须再召开股东会作批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618070909","title":"IPO「黑函」頻現 港交所「密交」擴容箭在弦上","url":"https://stock-news.laohu8.com/highlight/detail?id=2618070909","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618070909?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 21:12","pubTimestamp":1773234772,"startTime":"0","endTime":"0","summary":"如今，为破解这一痛点，港交所正酝酿一场意义深远的上市制度改革。针对递表上市的“黑函”对于拟上市公司而言，在递交上市申请与通过聆讯之间，通常有数月的时间窗口。香港中小上市公司协会主席席春迎对此表示认同。它允许拟上市公司在通过聆讯前，无需公开披露其上市申请文件，从而获得一个宝贵的“静默期”。港交所此次考虑扩大保密申请范围，其底气正来自于自2018年以来一系列上市制度改革的成功，尤其是“科企专线”的积极反馈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311211842a46162c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311211842a46162c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","80388","BK1131","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618393390","title":"銀諾醫藥-B(02591.HK)3月23日舉行董事會會議考慮及批准全年業績","url":"https://stock-news.laohu8.com/highlight/detail?id=2618393390","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618393390?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 17:07","pubTimestamp":1773133627,"startTime":"0","endTime":"0","summary":"格隆汇3月10日丨银诺医药-B(02591.HK)宣布，董事会会议将于2026年3月23日(星期一)举行，藉以(其中包括)考虑及批准公司及其附属公司截至2025年12月31日止年度之全年业绩及其刊发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260310/32057375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618349692","title":"銀諾醫藥新獸藥推進6000L產能工藝變更申報","url":"https://stock-news.laohu8.com/highlight/detail?id=2618349692","media":"兽药信息资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618349692?lang=zh_tw&edition=fundamental","pubTime":"2026-03-08 09:11","pubTimestamp":1772932277,"startTime":"0","endTime":"0","summary":"公司项目推进在马年开工首日，公司宣布以“稳定供应、加速创新”为核心方向，全力配合核心产品依苏帕格鲁肽α纳入2025年国家医保目录的落地执行，并推进6000L产能工艺变更申报，以保障医疗机构的用药需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308091946a4572e92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308091946a4572e92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617154781","title":"銀諾醫藥-B03月05日獲主力加倉53.6萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617154781","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617154781?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 16:16","pubTimestamp":1772698566,"startTime":"0","endTime":"0","summary":"03月05日, 银诺医药-B股价涨2.06%，报收22.74元，成交金额938.7万元，换手率0.10%，振幅6.91%，量比0.89。银诺医药-B今日主力资金净流入53.6万元，连续3日净流入，上一交易日主力净流入179.8万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为57.14%，平均涨幅为2.37%。该股近5个交易日下跌17.37%，主力资金累计净流入346.0万元；近20日主力资金累计净流入1741.8万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305162146a6a5cb16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305162146a6a5cb16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616559227","title":"浦東創新藥上市首年即進駐上海50+醫療機構，創新落地「不減速」！浦東全鏈條支撐顯成效","url":"https://stock-news.laohu8.com/highlight/detail?id=2616559227","media":"科Way","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616559227?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 17:22","pubTimestamp":1772616128,"startTime":"0","endTime":"0","summary":"浦东全链条赋能，创新落地“不减速”创新药如何在浦东实现高效研发、准入与应用？上市与应用在浦东“双提速”创新药械产品上市与应用的“提速”需要一套长效机制来支撑。据统计，在2025年，浦东新区共有8个国产1类新药、6个三类创新医疗器械获批上市。进入2026年，已有多款创新药械获批上市或正加速获批中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603041826549542f713&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603041826549542f713&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06978","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186566011","title":"銀諾醫藥-B（02591）2月股份變動月報：股本保持穩定","url":"https://stock-news.laohu8.com/highlight/detail?id=1186566011","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186566011?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 16:52","pubTimestamp":1772614332,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司于2026年3月4日发布截至2026年2月28日的证券变动月报表。报告显示，公司本月无新增股份发行或回购行为，股本结构保持稳定。公司注册资本合计为人民币456,819,349元，分为420,285,370股于香港联交所上市的H股，以及36,533,979股未上市股份。公司同时确认已符合香港联交所关于最低公众持股量的要求。公司声明将持续遵守香港联交所《上市规则》及相关法律规定。根据公告信息，本次月报由联席公司秘书杨东妍签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616559224","title":"銀諾醫藥-B盤中異動 股價大跌5.43%報23.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616559224","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616559224?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 09:32","pubTimestamp":1772587950,"startTime":"0","endTime":"0","summary":"2026年03月04日早盘09时32分，银诺医药-B股票出现异动，股价大幅跳水5.43%。截至发稿，该股报23.000港元/股，成交量4600股，换手率0.00%，振幅4.11%。资金方面，该股资金流入4700港元，流出7.0456万港元。银诺医药-B股票所在的生物技术行业中，整体跌幅为0.27%。其相关个股中，欧康维视生物-B、再鼎医药、东曜药业-B涨幅较大，振幅较大的相关个股有康诺亚-B、圣诺医药-B、泰格医药，振幅分别为8.15%、5.38%、5.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304093230a448d2d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304093230a448d2d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616592225","title":"世界肥胖日｜告別\"周拋\"針！銀諾醫藥積極探索\"每月一針\"減重新方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2616592225","media":"银诺医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616592225?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 09:00","pubTimestamp":1772586022,"startTime":"0","endTime":"0","summary":"银诺医药积极响应，致力于通过科学研究为肥胖管理提供新的可能。公司在研药物依苏帕格鲁肽α的中国减重IIb期研究取得积极结果，验证了\"每2周一次\"给药方案的潜力；同时，在澳大利亚开展的II期多中心研究正在探索\"双周+月制剂\"的更长效给药方案。结果显示，经过18周治疗受试者平均体重较基线下降10%，平均腰围减少8.4cm。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304092335a69fa908&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304092335a69fa908&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616380477","title":"銀諾醫藥-B盤中異動 早盤股價大跌5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616380477","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616380477?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 10:32","pubTimestamp":1772418725,"startTime":"0","endTime":"0","summary":"2026年03月02日早盘10时32分，银诺医药-B股票出现波动，股价大幅下挫5.40%。截至发稿，该股报26.300港元/股，成交量10.32万股，换手率0.02%，振幅4.68%。银诺医药-B股票所在的生物技术行业中，整体跌幅为4.46%。其相关个股中，正大企业国际、派格生物医药-B、美因基因涨幅较大，振幅较大的相关个股有百奥赛图-B、MIRXES-B、荣昌生物，振幅分别为7.30%、7.19%、6.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302103205a440053a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302103205a440053a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":120,"code":"91000000","status":"200"}]}}